Source comparison
Stacking CJC-1295 Ipamorelin Skin Elasticity: Protocol Comparison
CJC-1295 Monotherapy 1–2mg weekly None 20–30% above baseline 16–20 weeks Provides baseline elevation but lacks pulsatile amplitude. Slower onset, modest results Ipamorelin Monotherapy 200–300mcg 1–2× daily 25–35% above baseline 14–18 weeks Creates sharp pulses
This comparison does not assign a generated winner or score.
- CJC-1295 Monotherapy
- 1–2mg weekly
- None
- 20–30% above baseline
- 16–20 weeks
- Provides baseline elevation but lacks pulsatile amplitude. Slower onset, modest results
- Ipamorelin Monotherapy
- 200–300mcg 1–2× daily
- 25–35% above baseline
- 14–18 weeks
- Creates sharp pulses but no sustained signaling. Effects decay between doses
- CJC-1295 + Ipamorelin Stack
- 50–65% above baseline
- 10–14 weeks
- Synergistic. Sustained baseline + pulsatile peaks optimize fibroblast activation
- High-Dose Ipamorelin Only
- 400–500mcg 2× daily
- 30–40% above baseline
- 12–16 weeks
- Higher side effect risk (water retention, numbness) with marginal additional benefit
- CJC-1295 + GHRP-2 Stack
- 100–200mcg 2× daily
- 45–55% above baseline
- Effective but GHRP-2 elevates cortisol. Less ideal for skin health than ipamorelin